Business Wire08.12.20
Endologix Inc., a developer and marketer of innovative treatments for aortic disorders, announced that Vaseem Mahboob, chief financial officer (CFO), has left the company to become CFO of a private global healthcare company. Cindy Pinto, vice president, Financial Planning & Analysis, is assuming the duties of interim CFO in addition to her current responsibilities, and the company has initiated a search process for a permanent successor that will include both internal and external candidates.
“During his nearly five years at Endologix, Vaseem made immeasurable contributions as a key member of our executive team. His strong commitment to growing the company was instrumental in driving our strategic plan,” commented John Onopchenko, CEO of Endologix. “On behalf of the Board of Directors and the entire Endologix team, I thank Vaseem for his trusted partnership and his role in advancing the Endologix mission, and I wish him well in his new endeavor. Additionally, Cindy has been an integral part of the Finance team for nearly six years, and I am confident she will successfully lead the organization through this transition.”
Vaseem Mahboob commented, “I am immensely proud of what the team has accomplished at Endologix, and it has been an honor to work for a company that is making such a profound difference in the lives of EVAR patients. I know John and this team will carry on this mission, and I wish them all the best.”
“During his nearly five years at Endologix, Vaseem made immeasurable contributions as a key member of our executive team. His strong commitment to growing the company was instrumental in driving our strategic plan,” commented John Onopchenko, CEO of Endologix. “On behalf of the Board of Directors and the entire Endologix team, I thank Vaseem for his trusted partnership and his role in advancing the Endologix mission, and I wish him well in his new endeavor. Additionally, Cindy has been an integral part of the Finance team for nearly six years, and I am confident she will successfully lead the organization through this transition.”
Vaseem Mahboob commented, “I am immensely proud of what the team has accomplished at Endologix, and it has been an honor to work for a company that is making such a profound difference in the lives of EVAR patients. I know John and this team will carry on this mission, and I wish them all the best.”
